Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »
2/297 von 416    DIMDI: MEDLINE (ME60) © NLM
ND: ME11069729
PMID: 11069729
LR: 20061115
CED: 20010102
DCO: 20010215
Autoren: Fenton JI; Chlebek-Brown KA; Peters TL; Caron JP; Orth MW
Titel: The effects of glucosamine derivatives on equine articular cartilage degradation in explant culture.
Quelle: Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society; VOL: 8 (6); p. 444-51 /200011/
PM: Print
SU: IM
Sprache: English
CY: ENGLAND
JID: 9305697
ISSN: 1063-4584
Institution: Department of Animal Science, Michigan State University, East Lansing, Michigan 48824, USA.
DT: In Vitro; Journal Article; Research Support, Non-U.S. Gov't
Schlagwörter
CT: ACETYLGLUCOSAMINE/pharmacology; ANIMALS; CARTILAGE, ARTICULAR/*drug effects; CARTILAGE, ARTICULAR/metabolism; CULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSAMINE/*pharmacology; GLUCOSE/pharmacology; HORSES/*metabolism; LIPOPOLYSACCHARIDES/pharmacology; NITRIC OXIDE/metabolism; PROTEOGLYCANS/metabolism
CTG: ACETYLGLUCOSAMIN/Pharmakologie; TIER; KNORPEL, GELENK-/*Arzneimittelwirkungen; KNORPEL, GELENK-/Stoffwechsel; LABORKULTUREN, TECHNIKEN FÜR; DOSIS-WIRKUNGSBEZIEHUNG, ARZNEIMITTEL-; GLUCOSAMIN/*Pharmakologie; GLUCOSE/Pharmakologie; PFERDE/*Stoffwechsel; LIPOPOLYSACCHARIDE/Pharmakologie; STICKSTOFFMONOXID/Stoffwechsel; PROTEOGLYCANE/Stoffwechsel
TE: Lipopolysaccharides; Proteoglycans; Nitric Oxide/10102-43-9; Glucosamine/3416-24-8; glucose 6-(hydrogen sulfate)/3803-84-7; Glucose/50-99-7; Acetylglucosamine/7512-17-6
CR: 10102-43-9; 3416-24-8; 3803-84-7; 50-99-7; 7512-17-6
AB: OBJECTIVE: To determine whether glucosamine-3-sulfate, glucose-3-sulfate (control) and N-acetyl glucosamine inhibit experimentally induced degradation of equine articular cartilage explants similar to glucosamine HCl. DESIGN: Articular cartilage was obtained from the antebrachio-carpal and middle joints of horses (2-8 years old) killed for reasons unrelated to lameness. Cartilage discs were harvested from the weight-bearing region of the articular surface and cultured. Media were exchanged daily and the recovered media stored at 4 degrees C. On days 1 and 2 lipopolysaccharide (LPS, 10 microg/ml) was added to induce cartilage degradation. To evaluate the effects of different sources of glucosamine (on an equal molar basis), varying concentrations of glucosamine HCl (0.25, 2.5, or 25 mg/ml), glucosamine-3-sulfate (0.304, 3.04, or 30.4 mg/ml), or N-acetyl-glucosamine (0.256, 2.56, or 25.6 mg/ml) were added to the cultures. The glucose-3-sulfate control was added at 0.3075, 3.075 or 30.75 mg/ml. Nitric oxide and proteoglycan released into conditioned media and tissue proteoglycan synthesis and total tissue PG content were measured as indicators of cartilage metabolism. RESULTS: Glucosamine-3-sulfate consistently inhibited cartilage degradation in a manner similar to glucosamine HCl, while the effects of N-acetyl-glucosamine were highly variable and did not inhibit cartilage degradation. Glucose-3-sulfate did not inhibit cartilage degradation. CONCLUSION: Our results indicate that glucosamine sulfate also has the potential to prevent or reduce articular cartilage degradation similar to glucosamine HCl in vitro. The amine group at the carbon-2 position appears important for the effectiveness of the glucosamine derivative. The therapeutic value of N-acetyl-glucosamine remains questionable. - CNOTE: Copyright 2000 OsteoArthritis Research Society International.
» Volltext »

» Fenster schließen »